Curated News
By: NewsRamp Editorial Staff
March 24, 2025
GeoVax Labs Announces $4.5 Million Registered Direct Offering for Immunotherapies and Vaccines
TLDR
- Investors can take advantage of purchasing GeoVax Labs, Inc. stocks at a favorable price in a registered direct offering.
- GeoVax Labs, Inc. entered into a securities purchase agreement with a healthcare-focused institutional investor for the sale of stocks and warrants.
- GeoVax Labs' development of immunotherapies and vaccines against cancer and infectious diseases aims to create a healthier future for all.
- GeoVax Labs, Inc. awarded a contract for a 10,000-participant Phase 2b clinical trial for a next-generation COVID-19 vaccine, GEO-CM04S1.
Impact - Why it Matters
This news matters as it signifies GeoVax Labs, Inc.'s strategic move to secure funding for its clinical-stage biotechnology initiatives. The successful completion of the Offering will enable the company to further develop immunotherapies and vaccines against cancer and infectious diseases, potentially leading to groundbreaking advancements in the healthcare industry.
Summary
GeoVax Labs, Inc. has entered into a securities purchase agreement with a healthcare-focused institutional investor for the purchase and sale of shares of its common stock and warrants in a registered direct offering. The Offering is expected to raise approximately $4.5 million, with the proceeds intended for working capital and general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for the transaction.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, GeoVax Labs Announces $4.5 Million Registered Direct Offering for Immunotherapies and Vaccines
